444 N. Capitol Street, NW, Suite 414
Washington, D.C. 20001
Prostate cancer screening and treatment should be individualized based on the patient's history and risk level. The appropriateness of PSA testing should be based on a decision made between the patient and his physician.
What You Should Know
On May 3, 2013, the American Urological Association (AUA) released a new Clinical Guideline on the Early Detection of Prostate Cancer. The new guideline, which addresses screening in asymptomatic men of average risk of prostate cancer, updates the Association's Best Practice Statement on Prostate-Specific Antigen (PSA), originally released in 2009.
What the AUA is Doing
The AUA is committed to preserving patients' access to appropriate prostate cancer testing and is working at both the federal and local levels to educate lawmakers on this important issue. Nationally, the AUA is working with lawmakers to advance the USPSTF Transparency and Accountability Act and is monitoring legislative and regulatory activity at the state level.
114th Congress (2015 – 2016)
113th Congress (2013 – 2014)
What You Can Do
State-Specific Information on PSA Access and Coverage
Visit the AUA Advocacy Center for updates on alerts and calls to action on this issue.
Frequently Asked Questions about the 2013 AUA Guideline on Early Detection of Prostate Cancer
© 2017 American Urological Association Education and Research Inc. All Rights Reserved.